Schiavoni, Elisa
 Distribuzione geografica
Continente #
EU - Europa 362
NA - Nord America 353
AS - Asia 167
AF - Africa 3
SA - Sud America 1
Totale 886
Nazione #
US - Stati Uniti d'America 345
IT - Italia 101
SE - Svezia 84
SG - Singapore 61
CN - Cina 60
DE - Germania 56
FR - Francia 46
IE - Irlanda 22
ID - Indonesia 20
GB - Regno Unito 13
RU - Federazione Russa 10
CA - Canada 8
KR - Corea 8
FI - Finlandia 7
IN - India 5
IR - Iran 5
BE - Belgio 4
JP - Giappone 4
TR - Turchia 4
PL - Polonia 3
PT - Portogallo 3
CZ - Repubblica Ceca 2
ES - Italia 2
NL - Olanda 2
UA - Ucraina 2
AR - Argentina 1
CI - Costa d'Avorio 1
HR - Croazia 1
HU - Ungheria 1
LT - Lituania 1
MK - Macedonia 1
NG - Nigeria 1
RO - Romania 1
TN - Tunisia 1
Totale 886
Città #
Chandler 80
Singapore 51
Ashburn 38
New York 28
Rome 21
Dublin 20
Milan 20
Jakarta 19
Marseille 17
Beijing 12
Boardman 9
Moscow 8
Princeton 8
Seoul 8
Boston 7
Jacksonville 7
Los Angeles 7
Redmond 7
Bremen 6
Nürnberg 6
Paderno Dugnano 6
Houston 5
Nanjing 5
Paris 5
Wilmington 5
Cattolica 4
Dearborn 4
Helsinki 4
Lancaster 4
Munich 4
Pune 4
Toronto 4
Atlanta 3
Chelsea 3
Izmir 3
Kunming 3
Lisbon 3
Naples 3
Redwood City 3
San Diego 3
San Mateo 3
Shanghai 3
Tianjin 3
Washington 3
Ancona 2
Ann Arbor 2
Ardabil 2
Bentivoglio 2
Brussels 2
Cagliari 2
Casarano 2
Cassino 2
Fairfield 2
Florence 2
Frankfurt am Main 2
Fremont 2
Hamilton 2
Hangzhou 2
Kish 2
Kraków 2
Lanzhou 2
Logroño 2
Olbia 2
Oristano 2
Saint-Fons 2
Seattle 2
Waanrode 2
Abidjan 1
Arzachena 1
Augusta 1
Brno 1
Budapest 1
Busto Arsizio 1
Cambridge 1
Gdansk 1
Guangzhou 1
Hackney 1
Hebei 1
Hefei 1
Hirakata 1
Iesi 1
Kocaeli 1
Lagos 1
Lappeenranta 1
Lawrence 1
Leawood 1
Mar Del Plata 1
Massa 1
Millbury 1
Montreal 1
Monza 1
Nabeul 1
Nagoya 1
Nanchang 1
Newark 1
North Billerica 1
Nuremberg 1
Ottawa 1
Sacramento 1
Santa Clara 1
Totale 548
Nome #
Efficacy and Mechanisms of Action of Fecal Microbiota Transplantation in Ulcerative Colitis: Pitfalls and Promises From a First Meta-Analysis 135
Gut Microbiota in Health, Diverticular Disease, Irritable Bowel Syndrome, and Inflammatory Bowel Diseases: Time for Microbial Marker of Gastrointestinal Disorders? 131
Therapy experiences and preferences among patients with anemia: Results of a cross-sectional survey among Italian patients with inflammatory bowel disease 93
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy 64
Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study. 54
Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre 53
Changes in admissions, and hospitalization outcomes of IBD patients in an Italian tertiary referral center over a 13-year period 51
The awareness of the IBD nurse position among patients from an Italian tertiary IBD centre 50
The role of inflammatory bowel disease nurses for patients on biologic therapy during the COVID-19 pandemic 47
Gut Microbiota Signatures Are Associated With Psychopathological Profiles in Patients With Ulcerative Colitis: Results From an Italian Tertiary IBD Center 36
Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study 36
Effect of a multistrain probiotic on leaky gut in patients with diarrhea-predominant irritable bowel syndrome (IBS-D): a pilot study 34
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study 28
Transition from intravenous to subcutaneous biological therapies in inflammatory bowel disease: An online survey of patients 22
The educational role of IBD nurses in Italy in vaccinations: do not miss the moment for COVID-19 21
Serial Fecal Microbiota Infusions via Colonoscopy for Active Ulcerative Colitis: A Feasibility, Safety, and Translational Monocentric Italian Study 19
Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy 13
Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study 11
Effectiveness and Safety of Switching from Intravenous to Subcutaneous Vedolizumab Formulation in Inflammatory Bowel Disease Patients in Clinical Remission 9
Totale 907
Categoria #
all - tutte 5.079
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.079


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202028 0 0 0 0 3 6 7 0 6 1 5 0
2020/202120 0 0 0 5 1 1 3 0 2 2 5 1
2021/202288 4 1 6 4 3 3 1 6 0 18 21 21
2022/2023276 44 32 11 35 20 17 28 27 27 6 11 18
2023/2024248 9 35 20 17 12 40 19 7 15 17 29 28
2024/2025113 9 11 45 19 29 0 0 0 0 0 0 0
Totale 907